The significance of calprotectin, CD147, APOA4 and DJ-1 in non-invasive detection of urinary bladder carcinoma

Abstract

Aim of the study is to define the diagnostic accuracy of selected urinary protein biomarkers in the non-invasive detection of primary and recurrent urothelial carcinoma of the urinary bladder. The urinary levels of calprotectin, CD147, APOA4 and protein deglycase DJ-1 were examined in 255 individuals, including 60 controls with non-malignant urological disease, 61 patients with a history of urinary bladder cancer with negative cytology and negative cystoscopy and 134 patients with urinary bladder cancer. Urinary concentrations of biomarkers were determined by Enzyme-Linked Immunosorbent Assay (ELISA). During the follow-up of patients with non-muscle invasive bladder cancer (NMIBC), a group of 44 patients with cancer recurrence was compared to the group of 61 patients with a history of NMIBC but with no evidence of disease. Urinary concentrations of the evaluated markers did not reveal any significant difference between these groups. During the primary diagnosis, a group of 90 patients with primary bladder cancer and 60 subjects with benign disease were compared. Urinary levels of CD147 were not significantly higher in patients with tumors. The greatest diagnostic accuracy was observed in APOA4 (sensitivity 55.6, specificity 83.3, AUC 0.75), and lesser in calprotectin (sensitivity 39.4, specificity 87.7, AUC 0.66) and in DJ-1 (sensitivity 61.1, specificity 66.7, AUC 0.64), respectively. Apolipoprotein A4 may be used potentially as a supplemental urinary marker in the diagnosis of primary bladder cancer.

Virus Bioresistor (VBR) for Detection of Bladder Cancer Marker DJ-1 in Urine at 10 pM in One Minute

“…Liquid biopsies involve the detection in blood, urine, and other bodily fluids of nucleic acids, circulating tumor cells (in blood), or distinctive protein markers that signal the presence of a particular cancer. DJ-1, a 20.7 kDa protein, is elevated in the urine of people with bladder cancer (BC). , Presently, the measurement of DJ-1 in urine requires an enzyme-linked immunosorbent assay (ELISA), which is both slow and inconvenient. A biosensor for DJ-1 could accelerate its assessment for the detection of BC recurrence in patients who have undergone treatment for the disease.…”

“…With this modification, a limit-of-detection of (LOD DJ1 ) of 10 pM is achieved in urine (synthetic and human), coupled with a dynamic range of more than four orders of magnitude from 10 pM to 300 nM. This performance is clinically relevant because it allows for the detection of elevated DJ-1 in the urine of patients who have bladder cancer (≈ 100 pM). ,,, Importantly, the modifications to the VBR do not compromise either the speed or the simplicity of its operation. As before, the VBR operates in a dip-and-read modality and produces a stable, quantitative signal within 1.0 min.…”

“…DJ-1, a 20.7 kDa protein, is elevated in the urine of people with bladder cancer (BC). 2,3 Presently, the measurement of DJ-1 in urine requires an enzyme-linked immunosorbent assay (ELISA), which is both slow and inconvenient. A biosensor for DJ-1 could accelerate its assessment for the detection of BC recurrence in patients who have undergone treatment for the disease.…”

Identification of DEGs and transcription factors involved in H. pylori-associated inflammation and their relevance with gastric cancer

“…It is worth noting that the expression of APOA4, GCG, CYP3A4, XPNPEP2, and FOXP3, JUN were different between cancer and normal samples in TCGA database. APOA4 was reported to be closely related to urinary bladder cancer (Soukup et al, 2019). CYP3A4 is currently indicated for the treatment of ovarian and breast cancer (Fiszer-Maliszewska et al, 2018;Liu et al, 2019).…”

Peer Review #1 of "Identification of DEGs and transcription factors involved in H. pylori-associated inflammation and their relevance with gastric cancer (v0.1)"

“…It is worth noting that the expression of APOA4, GCG, CYP3A4, XPNPEP2, and FOXP3, JUN were different between cancer and normal samples in TCGA database. APOA4 was reported to be closely related to urinary bladder cancer (Soukup et al 2019). CYP3A4 is currently indicated for the treatment of ovarian and breast cancer (Fiszer-Maliszewska et al 2018;Liu et al 2019).…”